We’ve developed the first intelligent, phased nicotine cessation system that combines smart vaping hardware, behavioral science, and AI-powered support. NicX is more than a medical-grade device; it’s a platform for real behavioral change with the potential to help millions finally quit for good.

Our phased delivery system and proprietary lockout technology address the shortcomings of outdated cessation methods like patches, gums, and cold turkey attempts. By timing dosage, spacing usage, and providing personalized phase progression through AI, NicX improves quit outcomes while aligning with the habits, preferences, and psychology of today’s nicotine users.

In partnership with Case Western Reserve University and University Hospitals, we are preparing to launch an IRB-approved clinical trial. This study will measure real-world efficacy, craving reduction, and quit success across multiple demographics. Findings will support our regulatory pathway, clinical partnerships, and future public health programs.

At NicX, our mission is to set a new standard for smoking and vaping cessation, one that’s built on science, driven by empathy and made for the modern world. Through partnerships with hospitals, researchers, and health-forward organizations, we aim to bring life-saving innovation to the people who need it most.